Physician profile
Niravkumar A Naik
NPI 1447319512
$4,285.79
in general payments reported to CMS, 2019-2025
42 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.49 · 2021: $186 · 2022: $1,702 · 2023: $1,778 · 2024: $330 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,384.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $423.21 | 2022-2025 | Kisqali |
| Astrazeneca Pharmaceuticals LP | $330.14 | 2022-2024 | Imfinzi, Calquence |
| Eisai INC. | $295.84 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $291.04 | 2022-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $235.52 | 2022-2023 | Zejula, Jemperli |
| Celgene Corporation | $189.69 | 2023 | Pomalyst, Opdualag |
| Pfizer INC. | $184.38 | 2019-2025 | |
| Tempus Ai, INC | $170.40 | 2024-2025 | Xt Cdx |
| Coherus Oncology, INC. | $157.16 | 2021 | |
| Amgen INC. | $149.64 | 2022-2023 | Xgeva, Vectibix, Nplate |
| Taiho Oncology, INC. | $141.97 | 2022-2023 | |
| Gilead Sciences, INC. | $138.68 | 2021-2025 | Trodelvy |
| Genentech USA, INC. | $131.33 | 2023 | Tecentriq, Lunsumio, Polivy |
| Daiichi Sankyo INC. | $108.70 | 2022-2023 | Enhertu |
| Genzyme Corporation | $95.97 | 2022-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $86.47 | 2022-2023 | Padcev |
| Merck Sharp & Dohme LLC | $77.18 | 2022-2023 | Keytruda, Welireg, Lynparza |
| Array Biopharma INC | $75.71 | 2025 | Mektovi, Braftovi, Lorbrena |
| Cti Biopharma Corp. | $72.34 | 2022-2023 | Vonjo |
| Karyopharm Therapeutics INC. | $71.68 | 2022-2023 | Xpovio |
| Incyte Corporation | $69.33 | 2022-2023 | Jakafi |
| Adaptive Biotechnologies Corporation | $65.28 | 2022-2024 | Clonoseq |
| Puma Biotechnology, INC. | $63.20 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $61.24 | 2022-2023 | Imbruvica |
| Myriad Genetic Laboratories, INC. | $60.80 | 2022-2023 | Myrisk |
| Pharmacosmos Therapeutics INC. | $59.40 | 2023-2025 | Monoferric |
| Tactile Systems Technology INC | $54.90 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Sirtex Medical INC | $51.73 | 2023 | Sir-Spheres Microspheres |
| Regeneron Healthcare Solutions, INC. | $44.49 | 2022-2023 | Libtayo |
| Sobi, INC | $36.40 | 2022 | |
| Alexion Pharmaceuticals, INC. | $34.92 | 2022-2023 | Ultomiris |
| Beigene USA, INC. | $32.48 | 2023 | Brukinsa |
| Kite Pharma, INC. | $30.62 | 2022 | |
| Abbvie INC. | $29.97 | 2024 | |
| Immunogen, INC. | $28.88 | 2023 | Elahere |
| Foundation Medicine, INC. | $27.38 | 2022 | |
| Morphosys, US INC. | $23.02 | 2022 | |
| Pharmaessentia USA Corporation | $19.98 | 2023 | Besremi |
| Sandoz INC. | $19.44 | 2022 | |
| Telix Pharmaceuticals | $17.96 | 2023 | Illuccix |
| Pharming Healthcare, INC. | $14.38 | 2023 | Ruconest |
| Astellas Pharma US INC | $12.94 | 2023 | Xtandi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niravkumar Naik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.